Medication treatment options for methamphetamine use disorder (MUD) have been studied for decades yet remain urgently needed, with U.S. overdose deaths from psychostimulants increasing nearly 70 percent between 2020 and 2023. The ADAPT-2 clinical trial studies the use of extended release (ER) bupropion plus extended-release, injectable naltrexone to treat MUD in primary care practice settings. Among adults with moderate to severe MUD, the response among participants who received treatment was higher than the placebo group, including low attrition, high adherence to the trial regimen, reduced cravings and depression symptoms, and better quality of life and recovery. Learn why you should consider treating patients with MUD in your primary care practice with the ADAPT-2 regimen as an alternative to specialist or residential treatment in this 14-minute podcast from the National Institute on Drug Abuse Clinical Trials Network Dissemination Initiative (NIDA CTN DI).
Key moments in this video:
Read the full ADAPT-2 study in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2020214
Learn more through the STFM podcast, NIDA: A New Medication Option for the Treatment of Methamphetamine Use Disorder: https://open.spotify.com/episode/4DrB4vSUbYdDLKSQGniz1v
Find other NIDA CTN DI tools and resources for substance use disorders: https://nida.nih.gov/nidamed-medical-health-professionals/ctn-dissemination-initiative